Filtered By:
Condition: Hypertension
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 587 results found since Jan 2013.
Petits ARN interf érents : applications potentielles pour les néphrologues Small interfering RNA: potential applications for nephrologists
Nephrol Ther. 2022 Dec;18(6S1):6S1-6S6. doi: 10.1016/S1769-7255(22)00646-0.ABSTRACTSmall interfering RNA (siRNAs) are double-stranded RNAs of around 20 base pairs in length that trigger RNAi machinery, which promotes degradation of a target mRNA avoiding protein translation. SiRNAs are liver-targeted, using tris N-acetylgalactosamine (GalNAc) as the targeting ligand. This discovery received the Nobel Prize for medicine and physiology in 2006 and lead to substantial therapeutic advances. Application field and development of these siRNA has been very fast. Indeed, patisiran has been released in 2018 for hereditary transthyre...
Source: Nephrologie and Therapeutique - December 30, 2022 Category: Urology & Nephrology Authors: Sandrine Lemoine Marie Courbebaisse Source Type: research
Can siRNA Improve Compliance in Patients With Hypertension? Can siRNA Improve Compliance in Patients With Hypertension?
Patients achieve a reduction in systolic blood pressure of>15 mm Hg for as long as 8 weeks after administration of a single dose of zilebesiran.Medscape Medical News
Source: Medscape Cardiology Headlines - January 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Petits ARN interf érents : applications potentielles pour les néphrologues Small interfering RNA: potential applications for nephrologists
Nephrol Ther. 2022 Dec;18(6S1):6S1-6S6. doi: 10.1016/S1769-7255(22)00646-0.ABSTRACTSmall interfering RNA (siRNAs) are double-stranded RNAs of around 20 base pairs in length that trigger RNAi machinery, which promotes degradation of a target mRNA avoiding protein translation. SiRNAs are liver-targeted, using tris N-acetylgalactosamine (GalNAc) as the targeting ligand. This discovery received the Nobel Prize for medicine and physiology in 2006 and lead to substantial therapeutic advances. Application field and development of these siRNA has been very fast. Indeed, patisiran has been released in 2018 for hereditary transthyre...
Source: Nephrologie and Therapeutique - December 30, 2022 Category: Urology & Nephrology Authors: Sandrine Lemoine Marie Courbebaisse Source Type: research
